(Q82814128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Breast cancer: Should we assess HER2 status by Oncotype DX? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Michail Ignatiadis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christos Sotiriou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

6 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

12-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

HER-2 as a target for breast cancer therapy.

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

Gene-expression signatures in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.188

10.1038/NRCLINONC.2011.188

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143144%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference